Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
Trial details
- Registry ID
- NCT02736656
- Drugs studied
- SPN-812
TrialRedline tracks 26 clinical trials sponsored by Supernus Pharmaceuticals, Inc.: 11 Phase 3, 15 Phase 2.
Company identity checked against sources
Names as written in the registry records.
NCT02736656 · Supernus Pharmaceuticals, Inc.
Before: Sep 2026. After: Dec 2026.
NCT07141329 · Supernus Pharmaceuticals, Inc.
Before: Recruiting. After: Enrolling by invitation.
NCT06798896 · Supernus Pharmaceuticals, Inc.
Before: 258 participants (planned). After: 216 participants (planned).
Before: Oct 2026. After: Aug 2027.
NCT05518578 · Supernus Pharmaceuticals, Inc.
Before: 35 participants (planned). After: 60 participants (planned).
Before: Oct 2024. After: 31 Dec 2027.
NCT07226661 · Supernus Pharmaceuticals, Inc.
Before: Not yet recruiting. After: Recruiting.